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Abstract
Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited neurodegenerative disease caused by expansion of a CAG
repeat that encodes a polyglutamine tract in ATAXIN1 (ATXN1). Molecular and genetic data indicate that SCA1 is mainly
caused by a gain-of-function mechanism. However, deletion of wild-type ATXN1 enhances SCA1 pathogenesis, whereas
increased levels of an evolutionarily conserved paralog of ATXN1, Ataxin 1-Like, ameliorate it. These data suggest that a
partial loss of ATXN1 function contributes to SCA1. To address this possibility, we set out to determine if the SCA1 disease
model (Atxn1
154Q/+ mice) and the loss of Atxn1 function model (Atxn1
2/2 mice) share molecular changes that could
potentially contribute to SCA1 pathogenesis. To identify transcriptional changes that might result from loss of function of
ATXN1 in SCA1, we performed gene expression microarray studies on cerebellar RNA from Atxn1
2/2 and Atxn1
154Q/+
cerebella and uncovered shared gene expression changes. We further show that mild overexpression of Ataxin-1-Like
rescues several of the molecular and behavioral defects in Atxn1
2/2 mice. These results support a model in which Ataxin 1-
Like overexpression represses SCA1 pathogenesis by compensating for a partial loss of function of Atxn1. Altogether, these
data provide evidence that partial loss of Atxn1 function contributes to SCA1 pathogenesis and raise the possibility that
loss-of-function mechanisms contribute to other dominantly inherited neurodegenerative diseases.
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Introduction
Polyglutamine diseases are caused by the expansion of an
unstable translated CAG repeats that encode a polyglutamine tract
in unrelated proteins [1,2]. There are nine dominantly inherited
neurodegenerative disorders caused by expanded polyglutamine
tracts: Huntington’s disease (HD), spinobulbar muscular atrophy
(SBMA), dentatorubropallidoluysian atrophy (DRPLA), and six
spinocerebellar ataxias (SCA1–3, 6,7 and 17) [1–7]. Several
genetic studies have revealed that loss of the involved proteins in
humans and mice does not cause neurodegeneration, leading to
the conclusion that the polyglutamine expanded protein causes
disease by a dominant gain-of-function mechanism whereby it
confers toxic properties to the host proteins [8–14]. The
importance of protein context and sub-cellular localization has
been highlighted in SCA1 pathogenesis because expansion of the
polyglutamine tract is necessary but not sufficient to cause
neurodegeneration. For example, overexpression of polygluta-
mine-expanded ATXN1 that has a single serine residue mutated
to alanine (S776A) does not lead to Purkinje cell degeneration, and
overexpression of polyglutamine-expanded ATXN1 lacking a
functional nuclear localization signal or lacking the AXH domain
is not toxic in mice [15–17]. These data revealed key domains in
ATXN1 that are critical for SCA1 pathogenesis, and indicated
that mutant ATXN1 must be localized in the nucleus to exert
toxicity. Furthermore, these data suggest that perhaps normal
interactions or functions of ATXN1 are relevant to SCA1
pathogenesis.
Several protein interactors of ATXN1 have been identified to
date. Among these, there are various transcriptional regulators,
including the Capicua homolog CIC, SMRTER, HDAC3, GFI-1
and RORa. Some of these factors modify the pathogenesis of
SCA1 in mice and fly models [15,18–20]. For instance, Rora
haploinsufficiency results in enhanced pathogenesis in SCA1
transgenic mice [20]. Furthermore, SCA1 transgenic mice share
common gene expression changes with the staggerer mice, which
have a spontaneous mutation in the Rora gene that leads to
cerebellar defects and ataxia [20–22].
Recent evidence shows that altered interactions of ATXN1 with
its native partners contribute to SCA1 pathogenesis. Studies in the
knock-in mouse model of SCA1, Atxn1
154Q/+, show that polyglu-
tamine-expanded Atxn1 prefers the formation of a protein
PLoS Genetics | www.plosgenetics.org 1 July 2010 | Volume 6 | Issue 7 | e1001021complex with the RNA splicing factor RBM17 while concomi-
tantly diminishing the formation of Atxn1 complexes with CIC, a
transcriptional repressor [23]. These data suggest an endogenous
role of ATXN1 in transcriptional regulation that might be altered
in SCA1.
Even though much of the genetic evidence suggests that SCA1
is mainly caused by a gain-of-function mechanism, additional data
also suggest that partial loss of Atxn1 function might contribute to
pathogenesis. We demonstrated that removing the wild-type copy
of Atxn1 in the knock-in mouse model of SCA1 (Atxn1
154Q/2) leads
to worsened SCA1 phenotypes [23]. Moreover, phenotypes and
neuropathology in Atxn1
154Q/+mice are partially suppressed by the
mild overexpression of an evolutionarily conserved paralog, Ataxin-
1-Like (Atxn1L) [19,24]. Atxn1L shares high homology with Atxn1,
however it lacks the polyglutamine tract, and it interacts with all
tested proteins that bind to Atxn1 [19,24,25]. Together, these
studies indicate that altering the levels of wild-type Atxn1 and its
paralog Atxn1L results in strong modulation of SCA1 phenotypes.
Taken together, these data led us to hypothesize that SCA1
pathogenesis results from a gain-of-function mechanism, with
partial loss of Atxn1 function potentially contributing to the
disease. Since Cic protein levels are also reduced in the Atxn1
2/2
mouse model [18], we predict that loss of functional Atxn1-Cic
complexes could lead to common transcriptional defects in
Atxn1
2/2 and Atxn1
154Q/+ mice. Given the predicted role of
Atxn1 in transcriptional regulation, we set out to test this
possibility by performing microarray analyses on Atxn1
2/2 and
Atxn1
154Q/+cerebella. We show that Atxn1
2/2 and Atxn1
154Q/+mice
share many common transcriptional and molecular phenotypes,
some potentially involving alterations in Atxn1-Cic-mediated
transcriptional repression. Loss of Atxn1 function also results in
several cerebellar transcriptional changes in common with mice
lacking Rora, another transcription factor that genetically and
physically interacts with ATXN1. Finally, we demonstrate that
overexpression of the Atxn1-related gene Atxn1L can rescue some of
the molecular and behavioral defects caused by loss-of-function of
Atxn1, strongly suggesting that Atxn1L-mediated suppression of
SCA1 neuropathology could be due to restoration of the partial
loss of Atxn1 function component in the disease.
Results
Atxn1
2/2 mice share cerebellar transcriptional alterations
with Atxn1
154Q/+mice
To identify gene expression changes in SCA1 that might be due
to partial loss of function of Atxn1, we surveyed transcriptional
changes in Atxn1
2/2 and Atxn1
154Q/+mouse cerebella using the
Affymetrix mouse Exon Array ST 1.0 and searched for shared
expression alterations. These arrays potentially enable the
detection of even small fold changes due to the existence of
multiple probes sets for most transcripts. Early symptomatic (7-
week-old) Atxn1
154Q/+mice were used to reflect early changes in
SCA1 pathogenesis (Figure 1A). Due to a lack of overt phenotypes
in 7-week-old Atxn1 null mice [13], 16-week-old Atxn1
2/2 mice
were chosen in order to maximize the potential number of gene
expression changes detected. Each mutant allele was studied and
compared to age-matched wild-type littermates controls.
We observed a highly significant rate of concordance and
overlap between cerebellar expression profiles of Atxn1
2/2 and
Atxn1
154Q/+ mice (z = 11.9485, P-value,2.2e-16, Kendall-t test).
Applying a very stringent cutoff value (false discovery rate (FDR)–
corrected P,0.01, Fold change $|60.1| log2), we identified 197
transcripts that are significantly dysregulated in both mouse
models (Figure 1A). These 197 transcriptional changes account for
22.1% of all gene expression changes detected in Atxn1
154Q/+
cerebella (Figure 1A and Table S1). Remarkably, a majority of the
differentially regulated transcripts (135 out of 197, 68.5%) are in
the same direction in both mouse models. (Figure 1B). A
preponderance of down-regulated genes in both models is
observed (90 out of 197), followed by genes up-regulated in both
models (45 out of 197), with only less than a third (62 out of 197)
altered in an opposite direction (Figure 1B). These data suggest
that at least 15.1% (135 out of 892) of the cerebellar transcriptional
changes found in the SCA1 knock-in model (Atxn1
154Q/+) could be
attributed to loss of Atxn1 function.
To verify the microarray results, we selected 15 of these shared
gene expression changes for independent validation by quantitative
real-timereversetranscriptionpolymerasechainreaction(qRT-PCR)
using cerebellar RNA samples from an independent set of 16-week-
old Atxn1
2/2 and Atxn1
154Q/+mice, and their respective littermates.
Ten out of 15 gene expression changes, or 66.6%, were positively
validated in Atxn1
2/2 mice, while 13 out of 15 genes, or 86.7%, were
validated in Atxn1
154Q/+cerebella (Table 1). Most importantly, of the
10 genes validated in Atxn1
2/2 cerebella, 9 were also validated in
Atxn1
154Q/+cerebella (Table 1). Taken together, the comparison of
cerebellar microarray studies of Atxn1 null and polyglutamine-
expanded Atxn1 knock-in mouse models demonstrate that a
significant amount of transcriptional changes are shared between
these models, supporting the notion that some loss of Atxn1
endogenous function contributes to disease.
In order to gain insight into the potential molecular pathways
commonly affected in Atxn1
2/2 and Atxn1
154Q/+ mice, we
performed Gene Ontology (GO) analysis and pathway analysis
based on the Kyoto Encyclopedia of Genes and Genomes
(KEGG) (Figures S1, S2, S3, S4, S5, S6, and Table S2). GO
analysis revealed some biological functions that are enriched in
commonly dysregulated genes. For example, cell junction and
synapse, guanyl-nucleotide exchange factor activity and GTPase
activity categories were enriched in the common set of up-
regulated genes (Figures S1, S2, S3). In the down-regulated gene
set, genes encoding for calcium ion binding were the most
significantly affected both in Atxn1
154Q/+ and Atxn1
2/2 cerebella
(Figures S4, S5, S6). Using KEGG pathway analysis, among the
top enriched categories for genes commonly down-regulated in
Author Summary
Spinocerebellar Ataxia type 1 (SCA1) is one of nine
neurodegenerative diseases caused by an increase in the
number of the amino acid glutamine in their respective
proteins. Genetic studies have pointed to the fact that the
glutamine expansion in Ataxin-1 causes SCA1 by causing
Ataxin-1 togain some function(s). Here, we demonstrate that
in addition to the toxic gain-of-function mechanism, partial
loss of the normal functions of Ataxin-1 contributes to SCA1.
Ataxin-1 forms protein complexes with Capicua, a protein
that silences expression of other genes, and we found that in
SCA1 mouse models the levels of these complexes are
reduced,resultinginincreasedexpressionofsomegenes.We
also demonstrate that increased levels of Ataxin-1-Like, a
protein thatis similar to Ataxin-1 and protectsagainst mutant
Ataxin-1 in mice, rescues molecular and behavioral defects in
mice deficient in Ataxin-1. These results show that Ataxin-1-
Like compensates for loss of Ataxin-1 and that Ataxin-1 and
Ataxin-1-Like share some normal functions. Together, these
findings suggest that rescue of SCA1 symptoms by Ataxin-1-
Like could be partly due to restoration of lost normal
functions of Ataxin-1 in mice that express the mutant
polyglutamine-expanded Ataxin-1.
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2/2 and Atxn1
154Q/+ mice are the phosphatidylino-
sitol and calcium signaling, Long Term Depression (LTD)
associated genes, and Alzheimer’s disease pathways (Table S2).
These results strongly suggest that loss of Atxn1 results in
transcriptional changes that are potentially pathogenic, since in
addition to the enrichment for genes involved in neurodegenerative
disease, the phosphatidylinositol and calcium signaling pathways
are also known to be dysregulated in SCA1 models [26–28].
Interestingly, commonly up-regulated genes in Atxn1
2/2
and Atxn1
154Q/+ mice include genes that are involved in cancer
pathways (Table S2). This could potentially point to a novel
function of Atxn1 that remains to be clarified in proliferating cells.
The categories enriched for genes going in opposite directions
between Atxn1
2/2 and Atxn1
154Q/+ mice involve citrate cycle and
ubiquitin-mediated proteolysis. These genes going in opposite
directions are of interest, since they might reflect potential
differences reflecting the main gain of function mechanism in
SCA1 pathogenesis.
Atxn1
2/2 cerebella exhibit key pathological gene
expression changes present in staggerer mice
Given the significant overlap between the transcriptional
profiles of Atxn1
2/2 and Atxn1
154Q/+cerebella, we were interested
in examining whether these transcriptional changes are due to
Figure 1. Comparison of transcriptional profiles of Atxn1
154Q/+ and Atxn1
2/2 cerebella. (A) Venn diagram reporting the number of
significant gene expression changes in Atxn1
2/2 and Atxn1
154Q/+cerebella. A total of 197 transcripts were significantly altered in both Atxn1
2/2 and
Atxn1
154Q/+mice, using a p-value of less than 0.01, and a minimal fold change of |60.1| log2. (B) The majority of shared changes (68% of genes or 135
out of 197) went in the same direction.
doi:10.1371/journal.pgen.1001021.g001
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due to cerebellar dysfunction. Previous studies showed that
ATXN1 and RORa interact genetically and biochemically, and
deficiency of Rora enhances phenotypes in a transgenic model of
SCA1 [20]. Interestingly, we observed a significant overlap
between the genetic profiles of Atxn1
2/2 mice, and those
common between staggerer mice and SCA1 transgenic mice
(Table 2) [20,21]. Most of these shared changes between staggerer
and SCA1 mice are not present in Sca7
266Q/+ cerebella, a knock-
in mouse model for SCA7 [27], suggesting that most of these
changes are not due to cerebellar dysfunction or polyglutamine
disease in general (Table 2). We were able to confirm some of
these changes by real-time quantitative RT-PCR in cerebella
from 16-week-old Atxn1
2/2 mice, validating 4 out of 6
transcriptional changes tested (Figure S7). Given the known
genetic and physical interaction between ATXN1 and RORa
[20], these results could potentially indicate that Rora -dependent
transcriptional regulation is altered by loss of Atxn1 function. In
contrast to SCA1 transgenic mice, it is important to note that
Rora levels are not changed in Atxn1
2/2 mice [20]. Together,
these findings suggest that loss of endogenous function of Atxn1
results in transcriptional changes that could potentially contribute
to cerebellar pathogenesis.
Atxn1 and Capicua associate at the promoter regions of
genes altered in Atxn1
2/2 and Atxn1
154Q/+ cerebella
ATXN1 forms stable complexes in vivo with the Capicua
homolog (CIC), a transcriptional repressor that exhibits reduced
levels in Atxn1
154Q/+ mice [18,23]. To test the hypothesis that
reduced Atxn1-Cic complexes lead to dysregulated gene expres-
sion in Atxn1
154Q/+mice, we searched our microarray data for up-
regulated genes that are direct targets of Cic. Microarray analysis
revealed at least 3 significantly up-regulated genes (False Discovery
Rate-corrected P,0.05)i nAtxn1
2/2 cerebella that have been
identified as direct targets of Cic-mediated repression, namely
Etv1, Etv5 [29], and Ccnd1 (Fryer and Zoghbi, unpublished data).
Interestingly, the microarray data show that Etv5 and Ccnd1 are
also significantly up-regulated in Atxn1
154Q/+mice cerebella. These
results could reflect the fact that Cic protein levels are diminished
both in Atxn1
2/2 and Atxn1
154Q/+mice [18,23].
Table 1. Real-time qRT–PCR validation of genes commonly altered in Atxn1
154Q/+ and Atxn1
2/2 cerebella.
Gene symbol Atxn1
2/2 p-value Atxn1
2/2 Fold Change Atxn1
154Q/+ p-value Atxn1
154Q/+ Fold Change
Ifgbp5 0.0422 21.39 1.20E-05 23.55
Nab2 0.7402 21.04 0.0004 22.03
Rasal1 0.0095 21.45 2.78E-06 22.47
AW551984 0.1273 2.36 0.8609 21.12
Ldb2 0.5421 1.15 0.2139 21.36
Svep1 0.0099 1.27 0.0003 21.49
Apba2bp 0.0288 1.28 0.0001 21.51
Synpr 0.4993 1.26 0.0588 1.71
Adcyap1r1 0.1396 1.29 0.7922 1.05
Robo1 0.0002 1.62 0.0033 1.44
Tgfb3 4.76E-05 1.32 0.0254 1.16
Creb5 0.0012 1.44 0.0143 1.38
Ccnd1 4.61E-05 1.34 0.0018 1.23
Pafah1b3 4.09E-07 1.86 0.1448 1.12
Tiam2 2.09E-05 1.47 0.0149 1.17
Etv5 0.0078 1.35 0.8350 1.03
P-values for significant genes are represented in bold.
doi:10.1371/journal.pgen.1001021.t001
Table 2. Rora-responsive genes altered in SCA1 mouse
models and Atxn1
2/2 mice.
Gene
symbol Rora
(sg/sg)a
SCA1[82Q]
Tg
b Atxn1
2/2 Atxn1
154Q/+ Sca7
266Q/+c
Rora down down
Car8 down down down
Inpp5a down down down down down
Slc1a6 down down down
Actl6a down down down
Ccna2 down down
Atp2a2 down down down down
Itpr1 down down down down
Grid2 down down
Mela down down down
Calb1 down down down down down
Grm1 down down down
Nek2 down down
Id2 down down down down down
Spnb3 down down down
Pcp2 down down
Pcp4 down down down
Kitl down down down
Sst up up
aGold et al 2003 [21].
bSerra et al 2006 [20].
cGatchel et al 2008 [27].
doi:10.1371/journal.pgen.1001021.t002
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rationalized that both proteins should bind the promoter regions
of target genes if they mediate transcriptional repression together
as a complex. To test this possibility, we performed chromatin
immunoprecipition analysis, followed by PCR for the promoter
regions of Etv5 and Ccnd1 (ChIP-PCR). ChIP-PCR analysis using
antibodies against Cic confirmed that Cic is present on the
promoters of Etv5 and Ccnd1 in vivo (Figure 2A). To determine if
Atxn1 binds to the promoters of Cic targets and if the binding is
altered due to polyglutamine expansion, we prepared cross-linked
chromatin from mice expressing one wild-type Atxn1 allele
(Atxn1
+/2) and compared it to mice expressing one polygluta-
mine-expanded Atxn1 allele (Atxn1
154Q/2). We used Atxn1
2/2
mice as a negative control for testing Atxn1 antibody specificity. As
predicted, in chromatin extracts prepared from Atxn1
+/2 cerebella
and immunoprecipitated using Atxn1 antibody, wild-type Atxn1
was detected on the promoters of Etv5 and Ccnd1 (Figure 2B). In
contrast, we could not detect any specific signal for Atxn1[154Q]
above background levels in Atxn1
154Q/2 cerebellar chromatin
immunoprecipitations using Atxn1 antibodies (compared to
Atxn1
2/2 and pre-immune sera controls) (Figure 2B). These data
suggest that there is minimal association of polyglutamine-
expanded Atxn1[154Q] to the promoters of target genes in vivo.
Alternatively, it is possible that a conformational change in
Atxn1[154Q] renders it inaccessible for immunoprecipitation,
resulting in reduced signal.
Given that Atxn1[154Q]-specific signal is not detected on the
promoters of Etv5 and Ccnd1, we next asked if Cic protein can be
detected at these promoters in Atxn1
154Q/2 mice using Cic
antisera. We detected Cic binding to the promoter regions of
Etv5 and Ccnd1 (Figure 2C) on all genotypes tested (Atxn1
+/2,
Atxn1
154Q/2 and Atxn1
2/2), despite the fact that Cic protein levels
are reduced in Atxn1
2/2 and Atxn1
154Q/2 mice [18,23]. To better
quantify potential differences in Cic binding between the different
genotypes, we performed ChIP followed by quantitative PCR.
Primer sets designed for conserved regions in the promoters of
Etv5 and Ccnd1 that contain or are adjacent to Cic binding sites
(CBS) (TGAATGAA or TGAATGGA) were able to amplify with
no significant difference in all three genotypes (Atxn1
+/2,
Atxn1
154Q/2 and Atxn1
2/2), both for Etv5 and Ccnd1 (Figure 2D–
2E). To test for the specificity of Cic-binding to its consensus
sequences, primers were designed for regions lacking predicted
Cic-binding sites sequences, either upstream or downstream of the
CBS-containing regions in Etv5 and Ccnd1 promoters (Figure 2D–
2E). As expected, quantitative PCR for these regions show less
binding relative to the corresponding positive regions of Etv5 and
Ccnd1 by quantitative PCR. These findings suggest that although
Cic still binds the promoter, its function in repression is less
efficient in the absence of wild-type Atxn1 or that Atxn1L partially
compensates for the loss of Atxn1 at the promoters. The gene
expression and ChIP-PCR data suggest that polyglutamine-
expanded Atxn1 is less efficient in Cic-dependent repression.
More importantly, they provide evidence for a model in which loss
of Atxn1/Cic function can result in transcriptional dysregulation,
contributing to SCA1 pathogenesis.
Atxn1L
dp/+ rescues Cic levels in Atxn1
2/2 mice by forming
functional Atxn1L-Cic complexes
Given that mild overexpression of the Atxn1 paralog, Atxn1L,
can displace both wild-type and polyglutamine-expanded Atxn1
from large native complexes in a dose-dependent manner, we
wondered if Atxn1L could partially replace Atxn1 as a Cic binding
partner, especially because Atxn1L interacts with Cic in wild-type
cerebellum [19,24]. This led us to propose that in addition to
competing with Atxn1[154Q] in the large native complexes [24],
increased Atxn1L levels can suppress a putative loss of Atxn1
function in Atxn1
154Q/+ mice by directly substituting for Atxn1 in
Cic-containing complexes. To test this possibility, we generated
Atxn1
2/2 and Atxn1
2/2; Atxn1L
dp/+ littermates, and performed
western blot analysis for Cic. As shown in Figure 3A, Atxn1L
overexpression results in restoration of Cic levels back to wild-type
levels in Atxn1
2/2 cerebellum. We then tested if overexpression of
Atxn1L increased formation of Atxn1L-Cic complexes, thus
stabilizing Cic. For this, we performed co-immunoprecipitation
studies using Cic antibody on cerebellar extracts of Atxn1
2/2 mice
with or without the Atxn1L
dp allele, followed by western blot
analysis for Atxn1L. As expected, Atxn1L co-immunoprecipitates
with Cic in wild-type cerebella (Figure 3B). However, despite the
reduced levels of Cic protein in Atxn1
2/2 cerebella (Figure 3A and
[18]), the relative fraction of Atxn1L co-immunoprecipitated with
Cic in Atxn1
2/2 protein extracts was greater than in wild-type
cerebella (Figure 3B). Atxn1L overexpression further increased the
levels of Atxn1L-Cic co-immunoprecipitation in Atxn1
2/2;
Atxn1L
dp/+ mice (Figure 3B). These results suggest that Atxn1L
overexpression enhances the formation of Atxn1L-Cic complexes
in Atxn1
2/2 mice, thus stabilizing Cic protein levels.
We further asked whether Atxn1L-Cic complexes were
proficient in Cic-dependent transcriptional repression. For this,
we co-transfected HEK293T cells with a luciferase reporter
construct containing a tandem array of Cic binding sites [18,29],
along with Atxn1L and Cic-expressing plasmids. Consistent with
previous studies [18], co-transfection of Cic and Atxn1 resulted in
synergistic repression of the Cic-responsive luciferase reporter
(Figure 3C). Interestingly, co-transfection of constructs expressing
Cic and Atxn1L resulted in synergistic repression of the reporter
similar to co-transfection of Cic and wild-type Atxn1 (Figure 3C).
These results strongly suggest that Atxn1L-Cic and Atxn1-Cic
complexes are functionally redundant in Cic-dependent transcrip-
tional repression. Thus, we conclude that mild overexpression of
Atxn1L in Atxn1
2/2 mice might partially rescue a loss of Atxn1
endogenous function related to reduced Atxn1-Cic complexes.
Atxn1L
dp/+ restores some gene expression alterations in
Atxn1
2/2 mice
Given that mild Atxn1L overexpression rescues Cic levels in
Atxn1
2/2; Atxn1L
dp/+ mice, we predicted that Atxn1L should rescue
some of the transcriptional changes in Atxn1
2/2 cerebella if it can
functionally substitute for Atxn1.T ot e s tt h i s ,w ep e r f o r m e dq R T - P C R
on cerebellar RNA isolated from Atxn1
2/2; Atxn1L
dp/+ mice and
Atxn1
2/2 littermates at 16 weeks of age. We focused our qRT-PCR
analysis on the 9 genes that are commonly dysregulated in Atxn1
154Q/+
and Atxn1
2/2 cerebella (Table 1), and also on the 4 down-regulated
Rora targets validated by qRT-PCR in Atxn1
2/2 cerebellum (Figure
S7). Interestingly, 5 out of 13 genes tested (Ccnd1, Igfbp5,
Apba2bp, Robo1 and Grid2) were partially or completely restored back
to wild-type levels in Atxn1
2/2; Atxn1L
dp/+,c o m p a r e dt oAtxn1
2/2
cerebella (Figure 4A–4E). Ccnd1, one of the up-regulated genes that is
potentially a direct target of Atxn1-Cic complexes (Figure 4A), and
Igfbp5, an early key pathogenic marker in SCA1 disease (Figure 4B),
were among the genes rescued by Atxn1L overexpression in Atxn1
2/2
mice. Additionally, the Rora target Grid2 is also significantly rescued in
Atxn1
2/2; Atxn1L
dp/+ mice. Thus, mild overexpression of Atxn1L in vivo
results in partial rescue of several transcriptional changes related to
SCA1 pathogenesis in a loss-of-function model of Atxn1.S i n c eA t x n 1 L
binds to transcriptional regulators that interact with ATXN1, such as
CIC and SMRT-NCoR, it is possible that Atxn1L rescues
transcriptional changes by functionally replacing polyglutamine-
expanded Atxn1 in these transcriptional complexes.
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2/2 mice by
mild overexpression of Atxn1L
Although Atxn1
2/2 mice do not exhibit overt ataxia phenotypes
or progressive neurodegeneration, they do exhibit a variety of
neurological deficits ([13] and Figures S8, S9, S10, S11).
Interestingly, Atxn1
2/2 mice exhibit deficits in spatial learning
and memory, and in motor learning and coordination, phenotypes
shared with Atxn1
154Q/+mice ([13] and Figures S10 and S11). This
raises the possibility that partial loss of Atxn1 function of could also
contribute to these phenotypes in Atxn1
154Q/+mice. The fact that
the Atxn1L
dp allele can suppress behavioral phenotypes in
Atxn1
154Q/+mice [24] also raises the possibility that Atxn1L
suppresses SCA1 pathogenesis by functionally replacing those
Atxn1 functions altered by polyglutamine-expanded Atxn1.
To investigate whether Atxn1L and Atxn1 are functionally
redundant in vivo, we tested if the Atxn1L
dp allele can ameliorate
behavioral defects in Atxn1
2/2 mice. We focused on two
characteristic phenotypes clinically associated with SCA1 disease:
cognitive deficits (learning and memory) and deficits in motor
coordination and balance [30,31]. We performed the conditioned
fear paradigm on Atxn1
2/2 mice carrying the Atxn1L
dp allele and
compared them to Atxn1
2/2 littermates. As shown in Figure 5A,
and in agreement with previous data [32], Atxn1
2/2 mice
exhibited significant deficits, as determined by reduced freezing
behavior, in the contextual fear-conditioning test compared to
wild-type and Atxn1
+/2 littermates. Wild-type and Atxn1
+/2 mice
expressing the Atxn1L
dp allele performed similarly to the controls
(Figure 5A). Interestingly, the duplication of Atxn1L rescued the
freezing behavior due to loss of Atxn1 (compare Atxn1
2/2 mice to
Atxn1
2/2; Atxn1L
dp/+ mice; Figure 5A).
Having shown that mild overexpression of Atxn1L rescues
Pavlovian contextual learning in Atxn1
2/2 mice, we then wanted
to assess the effects of increased Atxn1L levels on motor
coordination and balance deficits in Atxn1
2/2 mice, another
phenotype common to SCA1 mouse models. In order to
discriminate between motor learning impairments and motor
coordination deficits, we chose to use the dowel rod and wire hang
tests. These paradigms do not rely on consecutive daily training, as
does the rotating rod test, therefore we selected them in order to
discern motor coordination and balance defects from cerebellar
learning deficits [33,34]. We generated an independent cohort of
Atxn1
2/2 mice and Atxn1
2/2; Atxn1L
dp/+ mice, with Atxn1
+/2 and
Atxn1
+/2; Atxn1
dp/+ littermates as controls, and tested them at 8
weeks of age. We measured the latency to reach the side (first
touch) and frequency of walking off the rod (number of side
touches in 120 seconds) (Figure 5B and 5C). All genotypes tested
remained on the dowel for the maximum time (data not shown),
but Atxn1
2/2 mice moved much less than Atxn1
+/2 and Atxn1
+/2;
Atxn1
dp/+ littermates on the rod. The latency of Atxn1
2/2 mice to
reach the side for the first time was increased (Figure 5B), and
consequently they walked off the rod fewer times (Figure 5C). It is
noteworthy that Atxn1
2/2 mice are active and travel the same
distance as wild-type littermates the open field analysis (Figure S5).
Thus the hesitancy to move on the dowel suggests that in addition
to learning and memory deficits, Atxn1
2/2 mice have balance or
motor coordination impairments, evident at an early age (8-week-
old). In contrast, Atxn1
2/2 mice carrying the Atxn1L
dp allele take
less time to walk off the dowel (Figure 5B), and they also crossed
the dowel more times in 120 s than Atxn1
2/2 littermates
(Figure 5C). Thus, mild Atxn1L overexpression partially rescues
the dowel phenotype caused by loss of Atxn1.
The wire-hang paradigm assesses motor coordination and grip
strength [34]. In this paradigm, mice are hanging onto the center of
an elevated wire from their forepaws, and they need to get to the
sides for relief, which requires coordination and normal strength.
We measured the time and frequency to reach the sides in a 120 s
interval, and found no significant falling off the wire in Atxn1
2/2
mice compared to the control littermates, suggesting that they have
reasonable grip strength (data not shown). However, Atxn1
2/2
mice showed increased latency to reach the sides for the first time
compared Atxn1
+/2 and Atxn1
+/2; Atxn1L
dp/+ controls (Figure 5D).
Additionally, Atxn1
2/2 mice reached the sides fewer times than
control littermates (Figure 5E). In contrast, Atxn1
2/2 mice
overexpressing Atxn1L exhibited marked reduction in the time for
the first touch and increased number of side touches in the 120 s
interval, when compared to Atxn1
2/2 mice (Figure 5D and 5E).
Taken together, these behavioral data demonstrate that a 50%
increase in the levels of AtxnlL is sufficient to partially rescue several
behavioral deficits caused by loss of Atxn1 function. Furthermore,
this rescue correlates with the molecular data, demonstrating that
Atxn1L is a functional homolog of Atxn1 in vivo.
Discussion
Recently, we proposed the possibility that in addition to toxic
gain-of-function due to polyglutamine-expanded ATXN1, a
concomitant partial loss of ATXN1 function might contribute to
SCA1 pathogenesis [23]. It is challenging to establish the extent of
the contribution of a potential loss-of-function mechanism to
SCA1 pathogenesis in models carrying the mutant protein, since
the severe gain-of-function effects might mask any subtle loss-of-
function component, thus confounding the interpretation of the
results. In the present study, we sought to distinguish between
gain- and loss-of-function mechanisms by focusing on transcrip-
tional defects in Atxn1
2/2 mice, and comparing them to the
knock-in model of SCA1, Atxn1
154Q/+ mice. Using this approach,
we identified several molecular changes that could be attributable
to loss of ATXN1 function in SCA1.
Figure 2. Chromatin immunoprecipitation (ChIP) reveals co-occupancy at the promoters of Cic target genes by Atxn1 and Cic. (A)
ChIP using Cic antisera confirmed Cic binding at the promoter of two direct targets of Capicua, Ccnd1 and Etv5, that were up-regulated in the
Atxn1
2/2 and Atxn1
154Q/+ cerebella. (B) ChIP using Atxn1 anti-sera in cerebellar extracts from Atxn1
+/2, Atxn1
154Q/2,a n dAtxn1
2/2 mice reveals a
signal in mice expressing only wild-type (Atxn1
+/2) but not polyQ-Atxn1 (Atxn1
154Q/2) compared to negative controls (pre-immune sera, and
Atxn1
2/2) (C) ChIP as in (B), this time using Cic antibody. In contrast to (B), Cic is present at comparable levels at the target promoters in Atxn1
+/2,
Atxn1
154Q/2,a n dAtxn
2/2 mice. All ChIP assays were repeated three times on independent samples, representative results shown. (D) ChIP followed
by quantitative PCR (ChIP-qPCR) on the promoter of Etv5 confirms that the proportion of immunoprecipitated DNA by Cic antibody is comparable
in all three genotypes (as seen in C). A region containing two Capicua binding sites (promoter-CBS) of Etv5 is more enriched by Cic antibody than a
region lacking CBSs (promoter-no CBS) compared to preimmune sera. (E) ChIP-qPCR on the promoter of Ccnd1 also shows similar enrichment of
immunoprecipitated DNA by Cic antibody in all three genotypes (as seen in C). ChIP-qPCR using primers designed for a region within 100 bps of
the CBS in the Ccnd1 promoter (which is highly conserved across species) show more Cic binding than primers designed for a poorly conserved
region further downstream (,400 bps) of the CBS at the promoter of Ccnd1, compared to preimmune sera. ChIP-qPCR experiments in (D) and (E)
were performed in triplicate on three independent sets of samples (3 cerebella per genotype) using SYBR Green Dye. N.S.=not significant,
** p,0.01, *** p,0.005.
doi:10.1371/journal.pgen.1001021.g002
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dp stabilizes Cic protein levels in Atxn1
2/2 mice by enhancing Atxn1L-Cic complex formation. (A) Western blot analysis
showsthatoverexpressionofAtxn1L rescues the reduced Cic levels in Atxn1
2/2mice(*p,0.05).(B)Co-immunoprecipitationofAtxn1LusingCicantibodies
show that, despite the reduced levels of Cic protein in Atxn1
2/2 cerebella, the relative fraction of Atxn1L co-immunoprecipitated with Cic in Atxn1
2/2
protein extracts was greater than in wild-type cerebella. Atxn1L overexpression further increased the levels of Atxn1L-Cic co-immunoprecipitation in
Atxn1
2/2; Atxn1L
dp/+ mice. Images show representative blots and the quantification of three independent experiments. Error bars in graphs represent +/2
SEM. * p,0.05. (C) To determine if Atxn1L-Cic complexes are functional, we measured the transcriptional effect of Cic, Atxn1 and Atxn1L on the expression
of a luciferase reporter construct containing a tandem array of Cic binding sites (CBS). Luciferase activity is expressed as fraction of the activity when the
reporter is expressed alone (100%). Co-transfection of Cic and Atxn1[2Q]) results in synergistic co-repression of this luciferase reporter (Cic+Atxn1[2Q]).
Interestingly, co-transfection of constructs expressing Cic and Atxn1L (Cic+Atxn1[2Q]) results in synergistic repression of the reporter similar to co-
transfection of Cic and wild-type Atxn1. These results suggest that Atxn1L-Cic complexes are functional in Capicua-dependent repression. Assays were
performed in duplicate in 5 independent experiments. Error bars in graph represent +/2 SEM, *p,0.05,***p,0.005.
doi:10.1371/journal.pgen.1001021.g003
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PLoS Genetics | www.plosgenetics.org 9 July 2010 | Volume 6 | Issue 7 | e1001021We found that loss-of-function of Atxn1 in mice is sufficient to
cause many transcriptional changes common to the Atxn1
154Q/+
knock-in mice, a model of SCA1 that faithfully replicates many
features of the disease, and with SCA1[82Q] transgenic mice. It has
been reported that ATXN1 interacts with several factors involved
in transcriptional regulation, including CIC, SMRTER, HDAC3,
Gfi1 and RORa [15,18–20]. Therefore, these shared expression
changes might be indicative of altered transcriptional functions of
ATXN1 in SCA1 pathogenesis. Furthermore, we showed that a
majority of the shared transcriptional changes go in the same
direction in both Atxn1
2/2 and Atxn1
154Q/+ mice, strongly arguing
that part of the transcriptional dysregulation in SCA1 might be
explained by a partial loss-of-function of Atxn1. The up-regulation
of direct targets of Atxn1-Cic provides evidence for this concept.
Another important finding of this study is that there are many
transcriptional changes that are unique to the Atxn1
154Q/+ model,
which could potentially be related to toxicity of polyglutamine-
expanded Atxn1.
We propose that a combination of toxic gain-of-function and
mild loss-of-function mechanisms contribute to SCA1 pathogen-
esis, with the partial loss-of-function of ATXN1 being sufficient to
cause some transcriptional changes that are pathogenic in the
cerebellum. Previous studies using microarray analysis reported on
the down-regulation of the dopamine receptor D2 (Drd2)i n
Atxn1
2/2 mouse cerebella [35]. However, with the exception of a
couple of genes (e.g. Pafahb3, Sp1), we were unable to find
extensive overlap between the changes reported by Goold et al.
and the microarray analysis presented in this study. The
differences in genetic background, microarray platform, and the
age of the Atxn1
2/2 animals (5-week-old) in the Goold et al. studies
[35], compared to 16 weeks in our studies, are likely to contribute
to the minimal overlap in gene expression changes in the two
studies.
Bioinformatics analyses of the genes commonly altered in
Atxn1
2/2 and Atxn1
154Q/+ cerebella show enrichment for catego-
ries associated with pathological pathways involved in neurode-
generation (Alzheimer’s disease), and also pathways previously
implicated in pathogenesis both in knock-in and transgenic SCA1
mouse models, such as the phosphatidylinositol and calcium
signaling pathways [26–28]. These results strongly suggest that
Atxn1
2/2 mice have dysfunctional cerebella due to a loss of
endogenous Atxn1 function. We also found that Atxn1
2/2 mice
share significant overlap in cerebellar transcriptional profiles with
staggerer mice, which have a spontaneous loss-of-function mutation
in the gene encoding the transcription factor Rora. Rora-
regulated genes involved in calcium signaling (Itpr1 and Calb1)
and glutamatergic signaling (Grm1 and Slc1a6) are significantly
down-regulated in Atxn1
2/2 cerebellum, as determined by
microarray analysis and real-time qRT-PCR. It is noteworthy
that loss-of-function mutations in several of these genes result in
ataxic phenotypes (e.g. Itpr1, Slc1a6, and Grm1) [36–38], raising the
possibility that simultaneous down-regulation of several of these
genes could contribute to the motor coordination impairments
observed in Atxn1
2/2 mice. Rora mRNA transcript and protein
levels appear normal in Atxn1
2/2 cerebellum [20], ruling out that
changes in Rora targets are due to reduced Rora protein levels in
Atxn1
2/2 mice. Since ATXN1 and Rora physically interact via
Tip60, it is conceivable that loss of Atxn1 affects Rora-dependent
transcription directly [20]. Altogether, these data support two
important conclusions: first, that Atxn1
2/2 cerebellum exhibits
pathological molecular changes, even in the absence of progressive
neurodegeneration, and second, that transcriptional changes in the
loss-of-function model of Atxn1 could identify endogenous
pathways that might also be altered by the expression of mutant
Atxn1.
We previously described a reduction of Atxn1-Cic complexes in
Atxn1
154Q/+cerebella, with Atxn1[154Q] favoring the formation of
enhanced toxic gain-of-function complexes with RBM17 [23]. It is
interesting that among the genes up-regulated both in Atxn1
2/2
and Atxn1
154Q/+cerebella, we identified two potential direct targets
of Cic-dependent repression, Ccnd1 and Etv5, the genes encoding
for Cyclin D1 and Ets variant 5, respectively ([29] and J. Fryer,
unpublished data). We demonstrated that wild-type Atxn1 and Cic
are bound to the promoter regions of Ccnd1 and Etv5.
Interestingly, we failed to detect mutant Atxn1[154Q] on these
promoters in mice only expressing expanded Atxn1 (Atxn1
154Q/2).
One interpretation of this result is that Atxn1[154Q] has
diminished association to the promoters, resulting in reduced
Atxn1-Cic dependent repression. Alternatively, it is possible that
polyglutamine-induced conformational changes make the
Atxn1[154Q]-Cic complexes less accessible for antibody recogni-
tion, resulting in reduced chromatin immunoprecipitation.
Irrespective of the basis of the inability to detect Atxn1[154Q]
binding on these promoters, the data strongly suggest that
polyglutamine-expanded Atxn1 and Cic have reduced transcrip-
tional repression function on these specific promoters in vivo. These
results provide a mechanistic explanation on how diminished
Atxn1-Cic function can contribute to transcriptional defects in
SCA1.
Mild overexpression of the evolutionarily conserved gene Atxn1L
partially suppresses the neuropathology caused by polyglutamine-
expanded ATXN1 in flies and mice [19,24]. Increased Atxn1L
levels induce the sequestration of polyglutamine-expanded Atxn1
into nuclear inclusions, leading to a proposed model in which
Atxn1L suppresses toxicity by displacement of mutant Atxn1 from
its major endogenous complexes that contain Cic [24]. In the
present study, we show an additional mechanism contributing to
this rescue, by demonstrating that mild overexpression of Atxn1L
suppresses several molecular and behavioral phenotypes in
Atxn1
2/2 mice, potentially by replacing Atxn1 in Cic-containing
complexes (Figure 6). The motor coordination and learning
deficits suppressed by Atxn1L are common to both Atxn1
2/2 and
polyglutamine-expanded Atxn1
154Q/+ mouse models. Therefore,
these data provide evidence for an additional mechanism in which
Atxn1L can functionally compensate for a partial loss of Atxn1
function to suppress SCA1 pathogenesis. Although our studies
demonstrate that Atxn1L is a functional homolog of Atxn1 in Cic-
mediated transcriptional repression, we cannot rule out that
Atxn1L overexpression can restore other yet to be determined
Atxn1-related functions not addressed in these studies. In sum,
based on our previous data and this study, we propose that partial
loss of ATXN1 function actively contributes to SCA1 pathogenesis
as part of a two-pronged mechanism, in which enhanced toxic
gain-of-function of polyglutamine-expanded ATXN1 leads to
neurodegeneration, while a simultaneous loss-of-function of other
Figure 4. Mild overexpression of Atxn1L restores expression levels of some genes altered in Atxn1
2/2 cerebella. Real-time quantitative
RT-PCR on RNA extracted from wild-type (n=8), Atxn1
2/2 (n=10) and Atxn1
2/2; Atxn1L
dp/+ cerebella (n=6) for (A) Ccnd1, (B) Igfbp5, (C) Apba2bp, (D)
Robo1, and (E) Grid2 reveals that these transcripts were restored close to wild-type levels in Atxn1
2/2; Atxn1L
dp/+ cerebellum. Real-time qRT-PCR
experiments were performed in triplicate for each sample. Error bars represent +/2SEM, *p,0.05.
doi:10.1371/journal.pgen.1001021.g004
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dp suppresses the behavioral deficits in Atxn1
2/2 mice. We assessed the effects of mild overexpression of Atxn1L on Atxn1
2/2
phenotypes (A) Mice of the following genotypes: Atxn1
+/+ (n=5), Atxn1
+/2 (n=12), Atxn1
2/2 (n=9), Atxn1
+/+; Atxn1L
dp/+(n=10), Atxn1
+/2;
Atxn1L
dp/+(n=17), and Atxn1
2/2; Atxn1L
dp/+(n=12), were tested at 8 weeks for contextual conditioned fear. Atxn1
2/2 mice exhibited significantly
reduced freezing behavior in the contextual fear-conditioning test compared to wild-type and Atxn1
+/2 littermates. However, Atxn1
2/2 mice carrying
the Atxn1L duplication performed significantly better than Atxn1
2/2 littermates in this task (p,0.05). Wild-type and Atxn1
+/2 mice expressing the
Atxn1L
dp allele performed similarly to wild-type and Atxn1
+/2 mice without the Atxn1L duplication. (B–E) An independent cohort of mice was generated
to test the effects of Atxn1L duplication on the motor deficits of Atxn1
2/2 mice. Atxn1
+/2 (n=16), Atxn1
+/2; Atxn1L
dp/+(n=23), Atxn1
2/2 (n=14), and
Atxn1
2/2; Atxn1L
dp/+ mice (n=17) were tested on the dowel andwire hang paradigms at 8 weeks. The latency of Atxn1
2/2 mice to reach the side for the
first time was increased compared to Atxn1
+/2 and Atxn1
+/2; Atxn1
dp/+ littermates on the rod (B); they also walked off the rod fewer times in the 120 s
interval (C). In contrast, Atxn1
2/2; Atxn1L
dp/+ mice took less time to walk off the dowel (B), and they also crossed the dowel more times in 120 s than
Atxn1
2/2 littermates (C). In the wire hang test, Atxn1
2/2 mice showed increased latency to reach the sides of the wire compared Atxn1
+/2 and Atxn1
+/2;
Atxn1L
dp/+controls (D). Additionally, Atxn1
2/2 mice reached the sides fewer times than control littermates (E). In contrast, Atxn1
2/2 mice overexpressing
Atxn1L exhibited marked reduction in the time for the first touch (D), and increased number of side touches in the 120 s interval, when compared to
Atxn1
2/2 mice (E). Error bars in graphs represent +/2 SEM, *p,0.05.
doi:10.1371/journal.pgen.1001021.g005
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the SCA1 phenotypes (Figure 6B).
It was previously reported that reduction of normal functions of
genes involved in other polyglutamine diseases results in enhanced
pathology, providing evidence for concomitant gain- and loss-of-
function mechanisms in polyglutamine disorders [39–43]. In
SBMA transgenic mouse models expressing polyglutamine-ex-
panded androgen receptor (AR), loss of endogenous AR protein
resulted in accelerated motor neuron degeneration [39]. These
studies suggested two independent pathways contributing to
SBMA pathogenesis: gain-of-function due to mutant AR nuclear
toxicity and loss of AR trophic effects on motor neurons [39].
Conditional deletion of Htt in mouse forebrain leads to several
features reminiscent of Huntington disease, including motor
deficits, tremors and progressive degeneration of the striatum
and cortex, hinting that loss of htt function could contribute to
Figure 6. Model of Atxn1L rescue through Cic stabilization in Atxn1
2/2 mice. (A) In wild-type mice, Atxn1-Cic and Atxn1L-Cic complexes
bind the promoters of target genes and repress them effectively. (B) In mice expressing polyglutamine-expanded Atxn1, mutant Atxn1 associates
preferentially with Rbm17, while the decrease in Atxn1-Cic complexes destabilizes Cic and reduces its levels at the promoters, thus leading to de-
repression of its target genes. (C) A similar Cic destabilization occurs in the absence of wild-type Atxn1 in Atxn1
2/2 mice, also resulting in increased
expression of target genes. (D) When Atxn1L is moderately overexpressed in Atxn1
2/2 mice, it stabilizes Cic levels by forming functional Atxn1L-Cic
complexes that can substitute for Atxn1-Cic at the promoters, thus rescuing target gene repression. We propose that this mechanism might also act
to rescue loss-of-function of Atxn1 in Atxn1
154Q/+; Atxn1L
dp/+ mice.
doi:10.1371/journal.pgen.1001021.g006
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function leads to enhanced neurodegeneration in transgenic
models expressing polyglutamine-expanded Htt, while overex-
pression of wild-type Htt reduces toxicity caused by mutant htt
[40–43]. The mechanism by which loss of Htt contributes to HD is
unclear at this time; it might involve either its anti-apoptotic
properties, its role in BDNF-mediated neuroprotection, both, or
some other yet to be determined function [44–47]. Our studies
comparing Atxn1
2/2 and SCA1 knock-in mice pinpoint Cic-
dependent transcriptional repression as one of the molecular
pathways mediating the partial loss-of-function component in
SCA1 pathogenesis.
Loss of normal endogenous function of mutant proteins may
also play a role in other dominant neurodegenerative diseases
caused by gain-of-function mutations. The Parkinson’s disease
model mice overexpressing the mutant A53T SNCA gene lacking
endogenous alpha-synuclein, exhibit worsened synucleinopathy
when compared to littermates carrying wild-type Snca alleles [48].
In Alzheimer disease (AD), increased aggregation of the amyloid
beta peptides induced by AD-related presenilin mutations is
thought to be a consequence of a dominant gain-of-function
mechanism [49]. However, loss of function of presenilin in the
mouse brain results in phenotypes strikingly reminiscent of AD
(progressive memory loss and neurodegeneration) in the absence of
beta-amyloid deposition [50,51]. These results suggest that altered
pathways leading to Alzheimer disease can be caused from a
combination of dominant gain of function and/or loss of function
mechanisms. The potential prevalence of mutations that lead to
both loss- and gain-of-function in human neurological diseases
underscores the importance of understanding the endogenous
functions of causative genes through the careful analysis of loss-of-
function models, which may uncover critical pathways leading to
pathogenesis.
Materials and Methods
Mouse lines
All mouse lines used in this study have been previously
described [9,13,24]. Atxn1
154Q/+ and Atxn1
2/2 mice have been
backcrossed into the C75Bl/6J strain for over ten generations. In
the case of Atxn1L duplication (Atxn1L
dp) mice, all experiments
described in this study were done in mice backcrossed for at least 7
generations into the C75Bl/6J strain. Atxn1
2/2 mice were bred to
Atxn1L
dp/+ mice, and Atxn1
2/2 mice carrying the Atxn1L duplication
locus were generated by intercrossing the progeny. Mouse
experiments followed protocols approved by the Baylor College
of Medicine Institutional Animal Care and Use Committee
(IACUC).
RNA isolation
Total RNA isolation from adult mouse cerebella was performed
as described elsewhere [52]. Briefly, RNA was extracted from
cerebella of 16-week-old mice using TRIzol reagent (Invitrogen
Corporation, Carlsbad, CA), DNaseI-treated, and purified using
the RNeasy mini kit according to the manufacturer’s protocol
(Qiagen, Valencia, CA).
Microarray analysis with exon arrays
We used the Affymetrix Mouse Exon 1.0 ST microarray, which
carries 1.2 million probe-sets covering one million exon clusters,
with an average of 40 probes per gene. The exon array data were
analyzed as previously described [52]. Briefly, raw data were
processed in the R statistical programming environment using
locally developed methods and the exonmap package. RMA
normalization was applied, and linear models were calculated to
analyze genotype effects for each gene. Genomic annotations were
obtained from UCSC (http://genome.ucsc.edu). The normalized
probe level data were then averaged within each exon to produce
exon-level data for each gene for each animal. A two-way
ANOVA with main effects for genotype and exonic region was
calculated for each gene. The ANOVA model was fit using
weighted least squares analysis where the weights were determined
according to the probe counts within each exon. Since separate
wild-type (WT) control littermates were used in the Atxn1
2/2 and
Atxn1
154Q/+ experiments, a separate linear model was estimated for
each gene in each model (one fit for each WT background). A
linear contrast was calculated comparing the WT and mutant
cross-exon means for each gene. The cut-off rule for determining
genes was a fold change threshold of +/20.1 in both experiments,
and a linear step up false discovery rate (FDR) of less than 0.01
value for the T-statistic corresponding to the linear contrast
comparing each WT strain with its corresponding mutant. The
gene set determined by this fold change and FDR multiplicity
corrected cutoff, corresponds to a median raw marginal p-value of
less than 0.00015 for the underlying T-statistics.
We performed Gene Ontology (GO) analysis on the obtained
data using locally developed software and methods [52]. Briefly,
the gene ontology vocabulary and current mouse annotations were
obtained from the GO website (9/1/2007 build). The mouse exon
array was mapped to Entrez identifiers, and these identifiers were
mapped to the GO data structure using the available annotations.
Using our local ontology analysis system (OntologyTraverser), we
tabulated the genes annotated at or below each GO node for the
entire exon array. We then used a hypergeometric sampling model
to examine the statistical representation of each GO node for
genes in our gene sets. In order to make comparisons between sets,
we took differences between the standardized scores determined
for each gene set. Because of the extreme overlapping structure of
the GO, many GO nodes report duplicate or redundant
information. To avoid this problem, we calculated the GO
covariance structure and used this estimate to compute de-
correlated GO scores. For the KEGG pathway analysis, the
overlapping gene list containing the 197 most significant genes was
uploaded and analyzed using the web-based Functional Annota-
tion Bioinformatics Microarray Analysis DAVID 6.7 (National
Institute of Allergy and Infectious Diseases NIH, david.abcc.
ncifcrf.gov/).
Real-time quantitative reverse transcriptase-polymerase
chain reaction (qRT–PCR)
For the independent validation of the exon array data, real time
qRT-PCR assays were performed on more than eight mice of each
genotype. cDNA was synthesized from 1 mg of RNA using the
RT2 First Strand Kit (SuperArray Bioscience Corporation,
Frederick, MD). Quantitative real-time PCR reactions were
performed on 10 ng of cDNA using RT2 SYBR Green/ROX
PCR master mix and commercially available primers (SuperArray
Bioscience Corporation, Frederick, MD). All RNA samples were
analyzed in triplicate and normalized relative to Gapdh levels.
For validation of Rora targets, cDNA was synthesized from
RNA isolated from seven Atxn1
2/2 mice and control littermates,
using Superscript III (Invitrogen). Quantitative real-time PCR
reactions were performed on 10 ng of cDNA using the SYBR
Green PCR Master Mix (Applied Biosystems) using the following
primer sets:
Itpr1 fw 59- GGGCCAACAGCACTACAGATG-39
rv 59-CTTCTTTTCCAAGTCTGCAGCAT-39
Grid2 fw 59- CCCGCATTGAGAGCTCCAT-39
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Inpp5a fw 59- TGGTCAAGAAAAGGCTTCATCA-39
rv 59- CCAAGTCGAAGGCACAGTCA-39
Grm1 fw 59- TCCTCTGACCTGAGACCAATAGC-39
rv 59- CGCGTTAGTGGCCATAAGCT-39
Chromatin Immunoprecipitation-polymerase chain
reaction analysis (ChIP-PCR)
ChIP was performed as previously described [52]. Cerebella
were dissected from mice of each genotype at 7–8 weeks of age
and incubated in 1% formaldehyde for 10 minutes at room
temperature to cross-link DNA to associated proteins. Chromatin
was treated with micrococcal nuclease and sheared by sonication
to generate fragments with an average length of ,100–200 bps, as
determined by agarose gel electrophoresis. For immunoprecipita-
tion, 200 ml of chromatin was diluted 1:10 in ChIP dilution buffer
(Millipore Corporation, Billerica, MA) and 1% of the diluted
sample was saved as input. The sample was first precleared with
protein A Dynabeads (Invitrogen Corporation, Carlsbad, CA),
then incubated overnight with protein A Dynabeads that were pre-
blocked with salmon sperm DNA and coupled to 20 ml of affinity
purified rabbit anti-Atxn1 (11NQ) antibody, or 4 ml of guinea pig
polyclonal anti-Cic antibody. Mock immunoprecipitations using
nonspecific preimmune sera for each antibody were included as
negative controls. After immunoprecipitation, the beads were
washed at room temperature with low salt buffer, followed by high
salt buffer, LiCl buffer (Millipore Corporation, Billerica, MA), and
TE buffer (10 mM Tris-HCl pH 7.4, 1 mM EDTA pH 8.0).
Elution was performed twice in 250 ml of fresh elution buffer (1%
SDS, 0.1 M NaHCO3) for 15 minutes at room temperature. The
eluates were combined, the crosslinks were reversed, and DNA
was purified with Qiagen PCR cleanup kit (Qiagen, Valencia, CA)
and recovered in 30 ml of 10 mM Tris-HCl pH 8.0. One or two ml
of DNA were used for each PCR reaction using primer pairs for
the promoter regions of the following genes:
Etv5 fw 59-GGGGAAGCTTAGCTGAGTCAGTGAA-39
rv 59- GTTTCTGTGTGTGGAATGACGAATTC-39
Ccnd1 fw 59-GGTTAACTGAATGGACTCCTAAGTTT-39
rv 59-GGAAATGTGTGTGAATAGTTCGCCTA-39
Capicua binding to the promoters was also analyzed using ChIP
followed by quantitative real-time PCR (SYBR green). Quantita-
tive real-time PCR experiments were performed in triplicate on
three independent sets of samples. Relative amounts of immuno-
precipitated DNA were determined based on the threshold cycle
(Ct) value for each PCR reaction. In order to control for variation
between ChIP fractions, for every gene promoter studied, a DCt
value was calculated for each sample (Atxn1
+/2, Atxn1
154Q/+,
Atxn1
2/2) by subtracting the Ct value for the input (CtInput) from
the Ct value for the immunoprecipitated sample (Ctantibody or
Ctpreimmune). Since the input DNA fraction represents only 1% of
the total material, the CtInput value was first adjusted for this
dilution factor by subtracting 6.644 cycles (Log2 of 100), then
substracted from the immunoprecipitated samples using the
following formula:
DCtantibody or Ctpreimmune

~ Ctantibody (or preimmune){ CtInput{6:644
 
:
Differences between the specific immunoprecipitation and the
preimmune serum background were then determined and plotted
as fold enrichment over the preimmune serum (for each genotype
sample: DCtantibody/DCtpreimmune).
Primer and sequences for the promoter regions used were as
follows:
Etv5 qA (highly conserved; two predicted Cic-binding sites):
fw 59- TTGCTCCTGATCACACATGC -39
rv 59- GCTGGAACCTCGTGAATGAT -39
Etv5 qB (conserved; ,1 Kb upstream of positive region Etv5
qA)
fw 59- AATCAGCACCGGCTTGTTTA-39
rv 59- CTAAGCTTCCCCCTCAGGTC-39
Ccnd1 qA (highly conserved; ,150 bp upstream of predicted
Cic-binding site)
fw 59- AAATTTGCATGAGCCAATCC-39
rv 59- GCAGAGCTCAACGAAGTTCC-39
Ccnd1 qB (poorly conserved; ,400bp downstream of predicted
Cic-binding site)
fw 59- GGTCGTGGTTAACTGAATGGA -39
rv 59- AGGTGGTGGAACCGCTTTAT-39
Co-immunoprecipitation studies
Cerebella from three mice of each genotype were dissected, and
dounce-homogenized in 1 ml of ice-cold TST buffer (10 mM
Tris–HCl, pH 7.5, 0.9% NaCl, 0.05% Tween 20). Protein was
adjusted to 0.5 mg in 200 ml with TST buffer (10 mM Tris–HCl,
pH 7.5, 0.9% NaCl, 0.05% Tween 20) and then added 800 ml
cold PBS. Fifteen microlitters of the extract were saved as input.
The extract was pre-cleared using protein A Sepharose beads.
BSA-blocked protein A Sepharose beads were coupled to 4 mlo f
polyclonal guinea pig anti-Cic serum or pre-immune serum for
1 hr at room temperature, and the diluted extract was incubated
with the antibody-coupled beads overnight at 4uC. Four washes
were carried out using ice-cold TST buffer and the pellet was
resuspended in sample buffer. Input and pellets were analyzed by
SDS-PAGE and protein blot.
Luciferase assays
Luciferase reporter assays for Cic-dependent repression were
performed as previously described [18]. HEK293T cells in 24-well
plates were co-transfected using Lipofectamine 2000 (Invitrogen)
with 50 ng of the pGL3-Promoter (Promega) containing six copies
of CIC binding sites (TGAATGAA or TGAATGGA), 10 ng of
pRL-TK, and 10 ng of expression plasmids for Atxn1[2Q] (wild-
type), Atxn1L and Cic-expressing plasmids as indicated. All
constructs have also been previously described [18,24]. The total
amount of DNA transfected was kept constant by adding
pcDNA3.1(-) (Invitrogen). Luciferase activities were measured
using the dual luciferase reporter assay system (Promega).
Contextual fear conditioning
For this task, the mice were trained in a novel environment with
a neutral stimulus (a tone) paired with a foot shock. The mice are
placed in a different context with the same tone (cued test) or back
in the same environment without a tone (contextual test) 24 h
later. Mice of each genotype were placed in a Med Associates/
Actimetrics chamber system where a 30 second tone was followed
by a 2 second foot shock at 1.5 mA. The tone–foot shock were
repeated at 2 min. Twenty-four hours later, the mice were tested
for freezing in the same chamber with no tone to evaluate
contextual fear. Scoring for freezing is automated in this system.
Analysis was performed using ANOVA and t-test analysis.
Dowel and wire hang paradigms
Mice were placed on the center of a 0.9 cm wooden dowel
suspended between two platforms. If the mouse walked off of the
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The test lasted 2 min beginning when the mouse was placed on
the dowel. Data were analyzed using ANOVA and Student’s t-test.
Supporting Information
Figure S1 Cellular component gene ontology for genes
commonly up-regulated in Atxn1
2/2 and Atxn1
154Q/+ cerebella.
Gene ontology categories shown were significantly enriched
(positive z score, green) or depleted (negative z score, green) with
the de-correlated z score for enrichment plotted in the x-axis. Only
gene ontology categories with more than one gene represented and
a z score.|+/22| are represented.
Found at: doi:10.1371/journal.pgen.1001021.s001 (0.24 MB TIF)
Figure S2 Biological process gene ontology for genes commonly
up-regulated in Atxn1
2/2 and Atxn1
154Q/+ cerebella. Gene
ontology categories shown were significantly enriched (positive z
score, green) or depleted (negative z score, green) with the de-
correlated z score for enrichment plotted in the x-axis. Only gene
ontology categories with more than one gene represented and a z
score.|+/22| are represented.
Found at: doi:10.1371/journal.pgen.1001021.s002 (0.53 MB TIF)
Figure S3 Molecular function gene ontology for genes com-
monly up-regulated in Atxn1
2/2and Atxn1
154Q/+ cerebella. Gene
ontology categories shown were significantly enriched (positive z
score, green) or depleted (negative z score, green) with the de-
correlated z score for enrichment plotted in the x-axis. Only gene
ontology categories with more than one gene represented and a z
score.|+/22| are represented.
Found at: doi:10.1371/journal.pgen.1001021.s003 (0.51 MB TIF)
Figure S4 Cellular component gene ontology for genes
commonly down-regulated in Atxn1
2/2 and Atxn1
154Q/+ cerebella.
Gene ontology categories shown were significantly enriched
(positive z score, green) or depleted (negative z score, green) with
the de-correlated z score for enrichment plotted in the x-axis. Only
gene ontology categories with more than one gene represented and
a z score.|+/22| are represented.
Found at: doi:10.1371/journal.pgen.1001021.s004 (0.38 MB TIF)
Figure S5 Biological process gene ontology for genes commonly
down-regulated in Atxn1
2/2 and Atxn1
154Q/+ cerebella. Gene
ontology categories shown were significantly enriched (positive z
score, green) or depleted (negative z score, green) with the de-
correlated z score for enrichment plotted in the x-axis. Only gene
ontology categories with more than one gene represented and a z
score.|+/22| are represented.
Found at: doi:10.1371/journal.pgen.1001021.s005 (0.74 MB TIF)
Figure S6 Molecular function gene ontology for genes com-
monly down-regulated in Atxn1
2/2 and Atxn1
154Q/+ cerebella.
Gene ontology categories shown were significantly enriched
(positive z score, green) or depleted (negative z score, green) with
the de-correlated z score for enrichment plotted in the x-axis. Only
gene ontology categories with more than one gene represented and
a z score.|+/22| are represented.
Found at: doi:10.1371/journal.pgen.1001021.s006 (0.73 MB TIF)
Figure S7 Real time qRT-PCR validation of Rora targets in
Atxn1
2/2 cerebella. Four out of six tested genes were significantly
down-regulated in Atxn1
2/2 cerebella. Error bars in graph
represent +/2 SEM *p,0.05.
Found at: doi:10.1371/journal.pgen.1001021.s007 (0.30 MB TIF)
Figure S8 Open Field Analysis to measure activity in pure
C57Bl/6J Atxn
2/2 mice. (A) Atxn1
2/2 mice at 10–11 weeks of age
spend more time in the center of the field compared to wild-type
littermates, suggesting they are less anxious. (B) Atxn1
2/2 mice and
wild-type littermates traveled similar total distances. (C) Atxn1
2/2
mice had decreased rearing, as measured by vertical activity in the
open field. Since Atxn1
2/2 mice show increased center/total
distance, their reduced vertical activity probably reflects motor
defects affecting rearing, and not increased anxiety. Error bars
represent +/2 SEM, **p,0.005.
Found at: doi:10.1371/journal.pgen.1001021.s008 (0.31 MB TIF)
Figure S9 Light/Dark box and Elevated Plus maze to test for
anxiety in pure C57Bl/6J Atxn1
2/2 mice. Atxn1
2/2 mice (n=10)
and wild-type controls (n=9) were tested at 12 weeks of age (A)
Atxn1
2/2 mice had a small trend to spend more time in the light
side than wild-type controls, although this trend does not reach
significance (p=0.26). (B) Both wild type and Atxn1
2/2 mice make
the same number of transitions between the light and dark side of
the box. (C) In the elevated plus maze, Atxn1
2/2 mice spent more
time in the open arms than controls, and (D) also made more arm
entries than controls. This shows that pure C57Bl/6J Atxn1
2/2
mice are not hypoactive, as reported before for Atxn1
2/2 mice in a
mixed C57Bl/6J/129svEv background. Error bars represent +/2
SEM, ***p,0.00001.
Found at: doi:10.1371/journal.pgen.1001021.s009 (0.44 MB TIF)
Figure S10 Conditioned Fear Analysis to measure Pavlovian
learning in Atxn1
2/2 mice. Seven mice of each genotype were
tested at 12 weeks of age. (A) In the contextual conditioned fear
test, mice were exposed to a tone paired to a foot shock and 24 hrs
later, placed in the same chamber and the amount of freezing
behavior is recorded, (B) In the cued test, only the tone is
administered in a different chamber and freezing is recorded.
Atxn1
2/2 mice show less freezing both in the contextual and cued
test (A and B), indicating amygdala and hippocampal deficits in
learning and memory. Error bars represent +/2 SEM,
*p,0.05,***p,0.001.
Found at: doi:10.1371/journal.pgen.1001021.s010 (0.27 MB TIF)
Figure S11 Dowel and wire hang analysis to measure gross
motor ability in Atxn1
2/2 mice. In the Dowel test for motor
coordination, mice are placed on a 0.9 cm rod and the time that it
takes to reach the side and number of side touches in 2 minutes is
recorded. Atxn1
2/2mice (n=11) and wild-type littermates (n=9)
were tested at 12 weeks. (A) Atxn1
2/2 mice performed poorly in
the dowel, with increased latency for to reach the sides for the first
time. (B) Atxn1
2/2mice also made less number of side touches in
2 min. (C and D) The wire hang test is similar to the dowel, except
a wire is used instead of a rod. Atxn1
2/2 mice had a trend to reach
the sides fewer times in 2 minutes than the controls (D), albeit not
significant (p,0.06) Error bars +/2 SEM, *p,0.05,**p,0.01.
Found at: doi:10.1371/journal.pgen.1001021.s011 (0.52 MB TIF)
Table S1 List of 197 commonly altered genes in Atxn1
2/2 and
Atxn1
154Q/+ cerebella. (p,0.01 Fold Change |+/20.1| log2
scale).
Found at: doi:10.1371/journal.pgen.1001021.s012 (0.37 MB
DOC)
Table S2 KEGG pathway analysis of the 197 commonly altered
genes in Atxn1
2/2 and Atxn1
154Q/+ cerebella.
Found at: doi:10.1371/journal.pgen.1001021.s013 (0.06 MB
DOC)
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